OMAHA, Neb. -- (BUSINESS WIRE) -- Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that the European Patent Office has issued a new patent, European Patent No. 21833798, covering one of its COLD-PCR family of DNA amplification technologies. The patent covers Full COLD-PCR, a foundation for the company’s highly sensitive ICE COLD-PCR technology. The COLD-PCR technology is owned by the Dana-Farber Cancer Institute, Boston USA, and exclusively licensed to Transgenomic.
Paul Kinnon, President and Chief Executive Officer of Transgenomic, commented, “This newly-issued patent provides broad intellectual property protection for a foundation of our ICE COLD-PCR technology, which enables researchers and clinicians to detect and monitor the genomic status of tumors by analyzing circulating tumor-derived DNA present in minute quantities in the blood or urine of patients. This approach has already demonstrated the potential to transform cancer research and treatment. It is expected to significantly improve patient care by enabling ongoing monitoring of response to therapy while reducing the need for invasive tissue biopsies.”
The new European patent helps extend the scope and longevity of the COLD-PCR intellectual property portfolio, which was originally developed by the laboratory of Dr. Mike Makrigiorgos at the Dana-Farber Cancer Institute. Transgenomic is also pursuing additional European patent coverage specific to ICE COLD-PCR technology.
ICE COLD-PCR can detect mutated tumor-derived DNA with high sensitivity in patient specimens that contain large amounts of “normal” DNA, such as blood, urine or tissue, thereby enabling DNA analysis of the tumor without the need for tissue biopsy.
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCRTM and its unique genetic tests provided through its Patient Testing business. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.
Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.